Welcome to our dedicated page for Bristol-Myers Squibb Co news (Ticker: BMY), a resource for investors and traders seeking the latest updates and insights on Bristol-Myers Squibb Co stock.
Bristol Myers Squibb (NYSE: BMY) generates frequent news across drug development, regulatory milestones, clinical data and corporate actions, reflecting its role as a global biopharmaceutical company focused on serious diseases. News coverage on this page centers on how the company’s cardiovascular, oncology, hematology, immunology and neuroscience programs progress from clinical trials to regulatory decisions and real-world use.
Recent updates have highlighted positive Phase 3 trial results for Camzyos (mavacamten) in adolescents with symptomatic obstructive hypertrophic cardiomyopathy in the SCOUT-HCM study, including statistically significant improvements in left ventricular outflow tract gradients and safety findings consistent with adult experience. Other headlines feature regulatory developments such as the U.S. Food and Drug Administration granting priority review to an Opdivo (nivolumab) plus chemotherapy combination for previously untreated advanced classical Hodgkin lymphoma, and the FDA’s approval of Breyanzi (lisocabtagene maraleucel; liso-cel) for adults with relapsed or refractory marginal zone lymphoma.
Investors and followers of BMY can also expect news on hematology research presented at major medical meetings, including data on investigational targeted protein degradation agents like golcadomide and BMS-986458, and long-term follow-up results for Breyanzi in large B-cell and follicular lymphomas. Corporate and financial items appear as well, such as dividend declarations, debt offerings, tender offers for outstanding notes, and presentations at healthcare investment conferences.
This news feed brings together company press releases, clinical trial readouts, regulatory updates, access and affordability agreements, and SEC-reported events. For users tracking BMY stock, it offers a single place to review how Bristol Myers Squibb’s pipeline, marketed products and capital markets activity evolve over time. Bookmark this page to quickly review new trial results, FDA decisions, access initiatives and financial disclosures related to Bristol Myers Squibb.
Bristol Myers Squibb (NYSE: BMY) announced positive topline Phase 3 SCOUT-HCM results showing Camzyos (mavacamten) met the primary endpoint with a statistically significant reduction in Valsalva LVOT gradient at Week 28 versus placebo in adolescents (ages 12 to <18).
The 44‑patient trial also met multiple secondary endpoints, reported safety consistent with the adult profile with no new signals, and continues into active treatment and a long‑term extension (totaling up to 200 weeks).
Bristol Myers Squibb (NYSE: BMY) will present at J.P. Morgan’s 44th Annual Healthcare Conference on Monday, January 12, 2026. The company's presentation and a fireside chat will begin at 7:30 a.m. PST / 10:30 a.m. ET.
The event will be webcast live at http://investor.bms.com, with presentation materials available at the start of the webcast. A replay and archived edition will be available after the event.
Bristol Myers Squibb (NYSE: BMS) announced an agreement with the U.S. government to improve affordability and supply resilience for Eliquis (apixaban).
Key items: Eliquis will be provided free to the Medicaid program starting January 1, 2026; the company will donate more than seven tons of Eliquis active pharmaceutical ingredient (API) to the U.S. Strategic Active Ingredient Reserve at no cost; BMS will receive three years of tariff relief; and BMS will enable direct-to-patient discounted access (about 80% off list price) for several branded medicines. The agreement’s specific commercial terms remain confidential. BMS reaffirmed a prior commitment to invest $40 billion in the United States over five years and said it will expand domestic production to support onshoring.
Bristol Myers Squibb (NYSE: BMY) will report results for the fourth quarter of 2025 on Thursday, February 5, 2026. Company executives will review financial results on a conference call beginning at 8:00 a.m. ET, with a live webcast available to investors and the public at http://investor.bms.com. Presentation materials will be posted to the same site before the call.
A replay of the webcast will be available at http://investor.bms.com approximately three hours after the conference call concludes. Contact emails: media@bms.com and investor.relations@bms.com.
Bristol Myers Squibb (NYSE: BMY) announced on December 11, 2025 that the U.S. FDA has accepted and granted priority review to the supplemental BLA for Opdivo (nivolumab) plus AVD for previously untreated Stage III or IV classical Hodgkin lymphoma in adults and pediatric patients 12 years and older. The FDA assigned a PDUFA target action date of April 8, 2026. The filing is supported by the randomized Phase 3 SWOG S1826 (CA2098UT) study, which lists progression-free survival as the primary endpoint and overall survival among key secondary endpoints. The study is sponsored by the National Cancer Institute and co-sponsored and supplied by Bristol Myers Squibb.
Bristol Myers Squibb (NYSE: BMY) announced a quarterly common-stock dividend of $0.63 per share, payable on February 2, 2026 to holders of record as of January 2, 2026. This quarterly rate is a 1.6% increase from last year’s $0.62 rate and implies an annual dividend rate of $2.52 for fiscal 2026 (subject to the board’s quarterly review). The company also declared a quarterly dividend of $0.50 per share on its $2.00 convertible preferred stock, payable March 2, 2026 to holders of record as of February 3, 2026. This marks the 17th consecutive year the company has increased the dividend and the 94th consecutive year the company has paid a dividend.
Bristol Myers Squibb (NYSE: BMY) presented lymphoma data at ASH 2025 highlighting targeted protein degradation and cell therapy advances. Key readouts: golcadomide plus R-CHOP showed a 24-month PFS of 79% with CMR 88% and MRD negativity 90%; golcadomide plus rituximab in FL showed ORR 97% and CRR 78%; BMS-986458 monotherapy showed ORR 65% overall. Long-term Breyanzi results: four-year PFS 52.2% and OS 61.5% in TRANSFORM; TRANSCEND FL 36-month CR 94% and DOR 70%. No new safety signals reported for investigational agents; Breyanzi safety profile reaffirmed.
Bristol Myers Squibb (NYSE: BMY) announced FDA approval of Breyanzi (lisocabtagene maraleucel) on December 5, 2025, as the first and only CAR T therapy for adults with relapsed or refractory marginal zone lymphoma (MZL) after ≥2 prior systemic therapies.
Approval was based on TRANSCEND FL MZL cohort results: ORR 95.5% (n=66), CR 62.1%, median duration of response not reached, and 90.1% of responders in response at 24 months; safety was consistent with prior data.
Terray Therapeutics announced on December 3, 2025 that it achieved a discovery milestone in its multi-target collaboration with Bristol Myers Squibb (NYSE: BMY). The milestone used Terray’s EMMI platform, which integrates generative AI, high-throughput chemical experimentation, and a rapidly expanding 13B+ target-ligand binding database with an automated lab.
The company said EMMI enables rapid, iterative discovery and optimization of novel small molecules for difficult-to-drug targets by combining advanced hardware, AI models, and structure-activity data to accelerate identification of development candidates for areas with significant unmet medical need.
Bristol Myers Squibb (NYSE: BMS) announced on December 3, 2025 that the ADEPT-2 Phase 3 study in psychosis associated with Alzheimer’s disease will continue with additional patient enrollment after a blinded review identified site-level irregularities.
The company excluded data from the affected sites before database lock, ran an independent interim efficacy and safety analysis with FDA consultation, and the Data Monitoring Committee recommended resuming enrollment to the original target population. BMS remains blinded to study data and expects ADEPT program readouts, including ADEPT-2, by end of 2026.